Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
Diabetes Care, Volume 32, No. 1, Year 2009
Notification
URL copied to clipboard!
Description
Objective- The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy. Research design and methods- In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutane-ously), to placebo, or to glimepiride (4 mg once daily). All treatments were in combination therapy with metformin (1g twice daily). Enrolled subjects (aged 25-79 years) had type 2 diabetes, A1C of 7-11% (previous OAD monotherapy for ≥3 months) or 7-10% (previous OAD combination therapy for ≥3 months), and BMI ≤40 kg/m2. Results- A1C values were significantly reduced in all liraglutide groups versus the placebo group (P < 0.0001) with mean decreases of 1.0% for 1.8 mg liraglutide, 1.2 mg liraglutide, and glimepiride and 0.7% for 0.6 mg liraglutide and an increase of 0.1% for placebo. Body weight decreased in all liraglutide groups (1.8-2.8 kg) compared with an increase in the glimepiride group (1.0 kg; P < 0.0001). The incidence of minor hypoglycemia with liraglutide (̃3%) was comparable to that with placebo but less than that with glimepiride (17%; P < 0.001). Nausea was reported by 11-19% of the liraglutide-treated subjects versus 3-4% in the placebo and glimepiride groups. The incidence of nausea declined over time. Conclusions- In subjects with type 2 diabetes, once-daily liraglutide induced similar glycemic control, reduced body weight, and lowered the occurrence of hypoglycemia compared with glimepiride, when both had background therapy of metformin. © 2009 by the American Diabetes Association.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC2606836/bin/dc08-1355_index.html
https://efashare.b-cdn.net/share/pmc/articles/PMC2606836/bin/dc08-1355_LEAD_2_Nauck_DCare_online_appendix_1.doc
Authors & Co-Authors
Nauck, Michael Albrecht
Germany, Bad Lauterberg
Diabeteszentrum Bad Lauterberg
Frid, Anders H.
Sweden, Lund
Öresund Diabetes Team ab
Hermansen, Kjeld
Denmark, Aarhus
Aarhus Universitetshospital
Shah, Nalini Samir
India, Mumbai
Seth gs Medical College and Kem Hospital
Tankova, Tsvetalina
Bulgaria, Sofia
Clinic of Diabetology
Mitha, Ismail Haroon
South Africa, Johannesburg
Benmed Hospital
Zdravkovic, Milan
Denmark, Bagsvard
Novo Nordisk A/s
Düring, Maria
Denmark, Bagsvard
Novo Nordisk A/s
Matthews, David Richard Md Dphil
United Kingdom, Oxford
University of Oxford Medical Sciences Division
Statistics
Citations: 774
Authors: 9
Affiliations: 8
Identifiers
Doi:
10.2337/dc08-1355
ISSN:
01495992
e-ISSN:
19355548
Research Areas
Disability
Health System And Policy
Noncommunicable Diseases
Study Design
Cohort Study